Besides the high specificity to DCs, such vaccines have been shown to effectively induce anti-tumor CD8+ and CD4+ T cell and humoral immune responses in mice in a lower dose, compared with the administration of non-targeted antigens [103]. The gene discussed is CD8A; the disease is neoplasm.